Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis

CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE[1])–Anokion[2] SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the initiation of patient dosing in its Phase 1 clinical trial to evaluate ANK-700 for the treatment of people with relapsing remitting multiple sclerosis (RRMS). The MoveS-it Study (Multiple Sclerosis Study of ANK-700 to Assess Safety and...

READ MORE Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis

ank partners with Mambu for a more intuitive financial experience

Mambu will provide ank with the enhanced agility, speed and flexibility of its cloud-native platform in order to increase its growing userbase and achieve the stated goal of ank of providing a simple, intuitive, secure and free way to send money between people, eliminating the time and stress generated by managing multiple bank accounts, complex keys that expire, password cards...

READ MORE ank partners with Mambu for a more intuitive financial experience

Angkor Resources’ Proposed 2020-21 Work Programs

TORONTO, Nov. 02, 2020 (GLOBE NEWSWIRE) — Angkor Resources Corp. (TSXV: ANK and OTC: ANKOF) (“Angkor” or “the Company”) CEO Stephen Burega is pleased to announce its 2020/21 work program which will include surface mapping through to drilling on its 100%-owned Andong Meas license including the Wild Boar and Canada Wall prospects as well as its 100%-owned Koan Nheak license...

READ MORE Angkor Resources’ Proposed 2020-21 Work Programs

Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis

CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE[1])–Anokion SA[2], a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS). Anokion plans to initiate a multi-center, Phase 1...

READ MORE Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis